P37.19 Activin-A and GDF-11 as Predictive Biomarkers for Platinum Response in Non-Small Cell Lung Cancer
نویسندگان
چکیده
Lung cancer is the leading cause of death in Australia with 13,000 new cases per year. Although targeted therapy and immunotherapy have drastically changed treatment landscape, majority patients will receive platinum-based chemotherapy for which response rate approximately 30% (Reck et al, 2016). An immunohistochemistry-based, predictive biomarker would be beneficial help avoid toxicity unlikely to respond. 3 potential biomarkers identified a paper by Marini al (2018) – activin A, growth differentiation factor-11 (GDF-11) transforming factor-b (TGF-B) –were investigated real-world retrospective cohort determine their relation objective radiological overall survival (Marini 2018). We 101 advanced non-small cell lung who received platinum at 2 centres between 2014-2015. Archival formalin-fixed paraffin embedded tissue samples were stained A GDF-11. Slides manually scored independent clinicians including specialist pathologist using multiplicative quickscore method, multiplies percentage tumour cells intensity staining 0-3+ create score out 18 (Detre 1995). performed Kaplan Meier analysis Cox-proportional hazards model confounding variables R software analyse relationship high immunohistochemistry scores (greater than median score) survival. chi square was expression response. statistical around cytoplasmic Activin-A (6) GDF-11 (12). The 15.3 months. No significant difference detected two populations (p value = 0.97) or (p=0.67). also not associated rates partial Activin 0.98) (p=0.56). Rates progressive disease levels 0.22) (p=0.12). Despite an association lower progression-free previous study, does appear predict setting cancer. Further research into TGF-B progress.
منابع مشابه
Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?
Lung cancer is the leading cause of cancer-related mortality in the United States. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most patients with NSCLC present with locoregionally advanced or metastatic disease, for which response rates and median overall survival remain poor. Platinum-based chemotherapy is the mainstay of treatment for NSCLC in both a...
متن کاملNon-small-cell lung cancer: which platinum for gemcitabine?
Cisplatin-based chemotherapy remains the backbone in the treatment of non-small-cell lung cancer (NSCLC), with significantly improved survival and better quality of life [1]. Platinum based doublets, with new drugs like Gemcitabine, Vinorelbine and Taxanes, are superior to single agent chemotherapy and should be preferred in first line treatment of patients with advanced NSCLC, according to cur...
متن کاملSerum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
PURPOSE To define the role of the DNA repair protein apurinic/apyrimidinic endonuclease 1 (APE1) in predicting the prognosis and chemotherapeutic response of non-small cell lung cancer patients receiving platinum-containing chemotherapy. RESULTS Our investigations found that serum APE1 level was significantly elevated in 229 of 412 NSCLC patients and correlated with its level in tissue (r2 = ...
متن کاملCirculating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.01.766